Document Detail


Treatment of congenital cytomegalovirus: where are we now?
MedLine Citation:
PMID:  17547508     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Congenital cytomegalovirus (CMV) is the most common congenital infection in the USA, affecting approximately 1% of all live births. While the majority of infants will remain asymptomatic, approximately 10% will be symptomatic at birth and another 10-15% will go on to develop problems during the first 6 years of life. Congenital CMV is now the most common cause of nonhereditary sensorineural hearing loss in children. Accordingly, researchers and clinicians have long been interested in identifying strategies to prevent or treat symptomatic congenital CMV infection. This article reviews congenital CMV with a focus on treatment strategies.
Authors:
Marian G Michaels
Related Documents :
19951848 - Circulating chemokine levels in febrile infants with serious bacterial infections.
15210678 - Gastrointestinal manifestations of postnatal cytomegalovirus infection in infants admit...
21319248 - Season of birth and subsequent body size: the potential role of prenatal vitamin d.
15665988 - Th-1 and th-2 cytokine production in infants with virus-associated wheezing.
19724018 - Ontogeny of methionine utilization and splanchnic uptake in critically ill children.
23689178 - Prediction of preterm birth.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Expert review of anti-infective therapy     Volume:  5     ISSN:  1744-8336     ISO Abbreviation:  Expert Rev Anti Infect Ther     Publication Date:  2007 Jun 
Date Detail:
Created Date:  2007-06-05     Completed Date:  2007-07-12     Revised Date:  2013-05-30    
Medline Journal Info:
Nlm Unique ID:  101181284     Medline TA:  Expert Rev Anti Infect Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  441-8     Citation Subset:  IM    
Affiliation:
University of Pittsburgh School of Medicine, Children's Hospital of Pittsburgh, Division of Infectious Diseases, Pittsburgh PA 15213, USA. marian.michaels@chp.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antiviral Agents / administration & dosage,  adverse effects,  therapeutic use*
Cytomegalovirus Infections / congenital*,  drug therapy*,  epidemiology
Cytosine / administration & dosage,  adverse effects,  analogs & derivatives,  therapeutic use
Female
Foscarnet / administration & dosage,  adverse effects,  therapeutic use
Ganciclovir / administration & dosage,  adverse effects,  analogs & derivatives,  therapeutic use
Humans
Infant, Newborn
Organophosphonates / administration & dosage,  adverse effects,  therapeutic use
Pregnancy
Chemical
Reg. No./Substance:
0/Antiviral Agents; 0/Organophosphonates; 0/valganciclovir; 4428-95-9/Foscarnet; 71-30-7/Cytosine; 82410-32-0/Ganciclovir; JIL713Q00N/cidofovir

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Recent developments in human cytomegalovirus diagnosis.
Next Document:  Vaccine strategies against human cytomegalovirus infection.